News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Ariad Pharmaceuticals, Inc. Not for Sale: CEO
March 31, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - Ariad Pharmaceuticals (ARIA.O), whose stock is trading at near five-year highs, is not looking to sell itself and is in partnership talks with large pharmaceutical companies in Japan for its leukemia drug, its chief executive said.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Immuno-oncology
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
October 28, 2026
·
2 min read
·
Tristan Manalac
Earnings
Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis
October 28, 2026
·
1 min read
·
Annalee Armstrong
Podcast
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
October 28, 2026
·
1 min read
·
Jef Akst
Business
US biotechs take lion’s share of $54.5B VC money raised since 2025
October 26, 2026
·
1 min read
·
Gabrielle Masson
